Bionano Genomics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring on August 31, 2020, regarding a Special Meeting of Stockholders held by Bionano Genomics, Inc. The filing details the voting outcomes and the subsequent adjournment of the meeting to solicit additional proxies.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
- Shareholder Approval: Stockholders approved Proposal 2, authorizing the adjournment of the Special Meeting to solicit additional proxies if necessary.
- Proposal 1 Outcome: Proposal 1, which sought to increase authorized common stock from 200,000,000 to 400,000,000 shares, failed to pass due to insufficient votes at the time of the meeting.
- Voting Statistics:
- Shares Outstanding (Record Date): 136,991,045
- Shares Present: 85,967,209
- Proposal 2 Votes For: 65,369,776
- Proposal 2 Votes Against: 17,815,754
- Proposal 2 Abstentions: 2,781,679
Outlook, Management Commentary, and Contingencies
The Special Meeting was adjourned and will reconvene on September 29, 2020, at 10:00 a.m. Pacific Time. Due to the COVID-19 pandemic, the reconvened meeting will be held virtually via live webcast only. The Company will continue to accept stockholder votes on Proposal 1 during the adjournment period.
Key Facts for Investor Verification
- Verify the final voting results for Proposal 1 (increase in authorized shares) after the reconvened meeting on September 29, 2020.
- Confirm the total number of shares voted in favor of Proposal 1 during the adjournment period.
- Monitor for any subsequent filings regarding the amendment to the Certificate of Incorporation if Proposal 1 is approved.